Halozyme’s story hinges on a single drug-delivery platform, and looming copycat competition plus tougher drug pricing could squeeze the fees it earns from partners. At the same time, more medicines are shifting to at-home injections where its technology can help, setting up a real tug-of-war between growth and margin pressure.Read more
More medicine makers are trying to move treatments from long clinic infusions to quicker injections people can take at home, and Halozyme sits in the middle of that shift through partnerships that can keep paying for years. The big question is whether patent fights, policy changes around drug costs, or a move to other ways of taking medicines could slow the stream of partner payments.Read more
Key Takeaways Halozyme benefits from the global shift to subcutaneous drug delivery, driving robust royalty growth and expanding margins through its ENHANZE platform and new biologic launches. Advancing proprietary technologies and efficient operations enable value-accretive deals, increasing revenue streams and supporting sustained earnings growth.Read more
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
